Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its recently published findings from its "Targeted Intra-tumoral Hyperthermia with Uniquely ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

Veracyte, Inc. , a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical ...

Urologist Practice Affiliation and Prostate Cancer - Poster Session Highlights SUO 2016: Association of Single Nucleotide Polymorphisms with Renal Cell Carcinoma Metastases in Patients with Dual ...

A team of researchers from the European Institute of Oncology and the Politecnico di Milano, coordinated by Luigi Nezi, Team ...

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Symptom scores remained stable over time, with similar QOL trends in both treatment arms.